Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
- Resource Type
- Article
- Source
- Oxidative Medicine & Cellular Longevity; 9/15/2021, p1-17, 17p
- Subject
- Language
- ISSN
- 19420900